Conclusions:

appears to be a 3.2-fold risk of lung cancer and 2.3-fold

risk of lung cancer mortality among patients randomized

to Exubera. There was no evidence of increased risk of all

cause mortality."

This doesn't sound great for Pfizer,but it's not going to help Afrezza's case either even if it is apples to oranges.

Thanks for sharing,MN.